

**Jubilant Biosys Innovative Research Services Pte Limited**  
**Balance Sheet as at 31 March 2021**

		USD	INR (' In Thousands)
	Notes		As at 31 March 2021
<b>ASSETS</b>			
<b>Non-current assets</b>			
Financial assets			
i. Non-current investments	1	31,56,736	2,30,789
<b>Total non-current assets</b>		<b>31,56,736</b>	<b>2,30,789</b>
<b>Current assets</b>			
Financial assets			
i. Cash and cash equivalents	2	1,43,254	10,473
Other current assets	3	1,261	93
<b>Total current assets</b>		<b>1,44,515</b>	<b>10,566</b>
<b>Total assets</b>		<b>33,01,251</b>	<b>2,41,355</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity Share capital	4	33,00,000	2,39,514
Other equity		(9,080)	1,086
<b>Total Equity</b>		<b>32,90,920</b>	<b>2,40,600</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Financial liabilities			
i. Trade payables	5	10,331	755
<b>Total current liabilities</b>		<b>10,331</b>	<b>755</b>
<b>Total liabilities</b>		<b>10,331</b>	<b>755</b>
<b>Total equity and liabilities</b>		<b>33,01,251</b>	<b>2,41,355</b>

**Benny Thomas**  
**Associate Vice President**

Place: Bangalore  
Date: 3 June 2021

**Jubilant Biosys Innovative Research Services Pte Limited**  
**Statement of Profit and Loss for the year ended 31 March 2021**

		USD	INR (' In Thousands)
	Notes	For the year ended 31 March 2021	
Revenue from operations		-	-
<b>Total income</b>		-	-
<b>Expenses</b>			
Other expenses	6	9,080	662
<b>Total expenses</b>		<b>9,080</b>	<b>662</b>
<b>Loss before tax</b>		<b>(9,080)</b>	<b>(662)</b>
Tax expense			
- Current tax		-	-
- Deferred tax		-	-
<b>Total tax expense</b>		-	-
<b>Loss for the year</b>		<b>(9,080)</b>	<b>(662)</b>
<b>Other comprehensive income</b>			
<b>Items that will be reclassified to profit or loss</b>			
Exchange differences on translation of foreign operations		-	1,748
<b>Other comprehensive loss for the year, net of tax</b>		-	<b>1,748</b>
<b>Total comprehensive loss for the year</b>		<b>(9,080)</b>	<b>1,086</b>

**Benny Thomas**  
**Associate Vice President**

Place: Bangalore  
Date: 3 June 2021

**Jubilant Biosys Innovative Research Services Pte Limited**  
**Statement of changes in equity for the year ended 31 March 2021**

**A) Equity Share Capital**

	<b>USD</b>
<b>Balance as at 1 April 2020</b>	<b>-</b>
Additions during the year	33,00,000
<b>Balance as at 31 March 2021</b>	<b>33,00,000</b>

**B) Other Equity**

	<b>USD</b>	
	<b>Reserves and Surplus</b>	
	<b>Retained earnings</b>	<b>Total</b>
<b>As at 1 April 2020</b>	<b>-</b>	<b>-</b>
Loss for the year	(9,080)	(9,080)
<b>Total comprehensive loss for the year</b>	<b>(9,080)</b>	<b>(9,080)</b>
<b>As at 31 March 2021</b>	<b>(9,080)</b>	<b>(9,080)</b>

**Benny Thomas**  
**Associate Vice President**

Place: Bangalore  
Date: 3 June 2021

**Jubilant Biosys Innovative Research Services Pte Limited**  
**Statement of changes in Equity for the year ended 31 March 2021**

**A) Equity Share Capital**

	INR (' In Thousands)
<b>Balance as at 1 April 2020</b>	-
Additions during the year	2,39,514
<b>Balance as at 31 March 2021</b>	<b>2,39,514</b>

**B) Other Equity**

	INR (' In Thousands)		
	Reserves and Surplus	Other Comprehensive Income	
	Retained earnings	Foreign currency translation reserve	Total
<b>As at 1 April 2020</b>	-	-	-
Loss for the year	(662)	-	(662)
Other comprehensive income for the year	-	1,748	1,748
<b>Total comprehensive (loss)/income for the year</b>	<b>(662)</b>	<b>1,748</b>	<b>1,086</b>
<b>As at 31 March 2021</b>	<b>(662)</b>	<b>1,748</b>	<b>1,086</b>

**Benny Thomas**  
**Associate Vice President**

Place: Bangalore  
Date: 3 June 2021

**Jubilant Biosys Innovative Research Services Pte Limited**  
**Statement of Cash Flows for the year ended 31 March 2021**

	USD	INR (' In Thousands)
	For the year ended 31 March 2021	
<b>A. Cash flow from operating activities</b>		
Loss before tax	(9,080)	(662)
<b>Operating cash flow before working capital changes</b>	<b>(9,080)</b>	<b>(662)</b>
Increase in trade and other receivables, other current assets	(1,261)	(92)
Increase in trade payables, provisions and other liabilities	10,331	753
<b>Cash used in operations</b>	<b>(10)</b>	<b>(1)</b>
Income tax and wealth tax paid (net of refund)	-	-
<b>Net cash used in operating activities</b>	<b>(10)</b>	<b>(1)</b>
<b>B. Cash flow from investing activities</b>		
Investment in subsidiaries	(31,56,736)	(2,30,284)
<b>Net cash generated from / (used in) investing activities</b>	<b>(31,56,736)</b>	<b>(2,30,284)</b>
<b>C. Cash flow arising from financing activities</b>		
Proceeds from issue of equity shares	33,00,000	2,40,735
<b>Net cash generated from financing activities</b>	<b>33,00,000</b>	<b>2,40,735</b>
<b>D. Effect of exchange rate changes</b>		
	-	23
<b>Net increase in cash and cash equivalents (A+B+C+D)</b>	<b>1,43,254</b>	<b>10,473</b>
Add: cash and cash equivalents at the beginning of year	-	-
<b>Cash and cash equivalents at the end of the year</b>	<b>1,43,254</b>	<b>10,473</b>

Benny Thomas  
Associate Vice President

Place: Bangalore  
Date: 3 June 2021

**Jubilant Biosys Innovative Research Services Pte Limited**  
**Notes to the financial statements for the year ended 31 March 2021**

**Note 1: Non-current investments**

	USD	INR (' In Thousands)
	As at	
	31 March 2021	
<b>Investment in subsidiary</b>		
Investment in TrialStat Solutions Inc	31,56,736	2,30,789
<b>Total Non-current investment</b>	<b>31,56,736</b>	<b>2,30,789</b>

**Note 2: Cash and cash equivalents**

	USD	INR (' In Thousands)
	As at	
	31 March 2021	
<b>Balances with banks</b>		
In current accounts	1,43,254	10,473
<b>Total cash and cash equivalents</b>	<b>1,43,254</b>	<b>10,473</b>

**Note 3: Other current assets**

	USD	INR (' In Thousands)
	As at	
	31 March 2021	
Prepaid expenses	1,261	93
<b>Total other current assets</b>	<b>45,547</b>	<b>93</b>

**Note 4 : Equity share capital**

	USD	INR (' In Thousands)
	As at	
	31 March 2021	
<b>Issued, subscribed and paid up</b>		
Equity shares	33,00,000	2,39,514

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

3) The details of shareholders holding more than 5% shares in the Company:

	As at	
	31 March 2021	
	No of shares	% holding in the class
<b>Name of the Shareholder</b>		
Jubilant Biosys Limited	33,00,000	100%

4) The reconciliation of the number of shares outstanding as at beginning and at end of the reporting period

	No of shares	USD	As at 31 March 2021 (Rs in thousand)
Numbers of shares at the beginning of the year	-	-	-
Add: Shares issued during the year	33,00,000	33,00,000	2,39,514
Number of shares at the end of the year	<b>33,00,000</b>	<b>33,00,000</b>	<b>2,39,514</b>

5) Equity shares held by holding company/ultimate holding company is set out below:

	As at	
	31 March 2021	
	No of shares	
Jubilant Biosys Limited	33,00,000	

**Jubilant Biosys Innovative Research Services Pte Limited**  
**Notes to the financial statements for the year ended 31 March 2021**

**Note 5: Trade payables**

	<b>USD</b>	<b>INR (' In Thousands)</b>
		<b>As at 31 March 2021</b>
Trade payables	10,331	755
<b>Total trade payables</b>	<b>10,331</b>	<b>755</b>

**Note 6: Other expenses**

	<b>USD</b>	<b>INR (' In Thousands)</b>
		<b>As at 31 March 2021</b>
Auditors remuneration	2,500	182
Legal and professional fees	6,570	479
Bank charges	10	1
<b>Total other expenses</b>	<b>9,080</b>	<b>662</b>